Overcoming Resistance in HER2+ Metastatic Breast Cancer: Inhibiting HER2 Signalling More Effectively w/ Dual Blockade, Antibodies, Bispecific Antibodies, Novel TKIs, Anti-HER2 + CPis, CDK4-6 or PI3K/AKT/mTOR
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Sernaz Uzunoğlu
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Sernaz Uzunoğlu
Comments 0
Login to view comments.
Click here to Login